Helpful resources to help you with your patients

Click on the image to play a video from a Key Opinion Leader

Tools for physicians

Download or print these resources to track your patient's progress. Instruct patients about taking
RAZADYNE ER or simply request your requirement of samples.

Tear Pad
Request Samples and
Additional Information
Observation Log
eDetail
ePocrates

Tear Pad

Simple instructions in an easy-to-read format

The Tear Pad provides you with a quick way to give your patients instructions about how to take RAZADYNE ER and how to switch from RAZADYNE to RAZADYNE ER. Simply tear off a sheet and hand the instructions to your patients or their caregivers.

Download the Tear Pad

Request Samples and Additional Information

The RAZADYNE ER Sample Pak contains everything you need to get patients started on RAZADYNE ER.

To order your Sample Pak containing 4-week supply of 8 mg RAZADYNE ER capsules, simply download and fax the request form.

Request a Sample Voucher Pak

Observation Log

A tool for caregivers

Monitoring and preparing for the progression of symptoms is an important part of caring for the patient with Alzheimer's disease. The Observation Log is an easy-to-use tool that allows caregivers to track the condition and progression of symptoms in patients with dementia of the Alzheimer's type, especially between visits to their healthcare professional. When returned at office visits, the Observation Log provides healthcare professionals with a quick update about the patient‘s symptom progression and response to therapy.

Download the Observation Log

eDetail

Too busy during office hours? Participate in eDetailing

If you'd like to get the advantages of a visit from a RAZADYNE ER representative—at a time that's more convenient to you—consider eDetailing. Each interaction will take approximately 10 minutes. You'll have hands-on access to data about RAZADYNE ER efficacy, safety & tolerability data, tools for you and your patients, and much more. Participate in one of many eDetail interactions available.

Start now

ePocrates

Access to drug, disease, and diagnostic information

Access to ePocrates information database can provide you with immediate access to drug, disease, and diagnostic information in a concise and convenient format. Also, stay informed on the latest industry news.

Sign up now

IMPORTANT SAFETY INFORMATION

Most frequent adverse events
In clinical trials, the most frequent adverse events with RAZADYNE ER were similar to those seen with RAZADYNE.

The most frequent adverse events that occurred with RAZADYNE were nausea, vomiting, diarrhea, anorexia, and weight loss.

Anesthesia
Cholinesterase inhibitors, such as galantamine HBr, are likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia.

Cardiovascular events
Because of their pharmacological action, cholinesterase inhibitors have vagotonic effects on the sinoatrial and atrioventricular (AV) nodes, leading to bradycardia and AV block. These actions may be particularly important to patients with supraventricular cardiac conduction disorders or to patients taking other drugs concomitantly that significantly slow heart rate. In clinical trials, galantamine HBr was associated with more frequent reports of bradycardia and syncope vs placebo.

Gastrointestinal
Cholinesterase inhibitors may increase gastric acid secretion. Patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk of developing ulcers, eg, those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs.

Genitourinary
Cholinesterase inhibitors may cause bladder outflow obstruction.

Neurological conditions
Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. In clinical trials, there was no increase in the incidence of convulsions with galantamine HBr compared with placebo.

Pulmonary conditions
Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

Deaths in subjects with mild cognitive impairment (MCI)
In controlled trials in elderly subjects with MCI, 13 subjects on RAZADYNE (n=1026) and 1 subject on placebo (n=1022) died of various causes. About half of the RAZADYNE deaths appeared to result from various vascular causes (myocardial infarction, stroke, and sudden death). RAZADYNE and RAZADYNE ER are not indicated for the treatment of MCI.

Hepatic or renal impairment
In patients with moderately impaired hepatic or renal function, dose titration should proceed cautiously. The use of RAZADYNE or RAZADYNE ER in patients with severe hepatic impairment or severely impaired renal function
(Cl_cr <9 mL/min) is not recommended.

Please see full Prescribing Information.

© Ortho-McNeil Neurologics, 2008. All rights reserved. Your use of the information on this site is subject to our Legal Notice. Please see our Privacy Policy. This site is published by Ortho-McNeil Neurologics, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents. The TOPAMAX360.com, RAZADYNEER360.com, TOPAMAXEPILEPSY360.com, and AXERT360.com sites are directly affiliated with OMN360.com and the same terms of use apply across all sites.

This information is intended for the use of our customers, patients and healthcare professionals in the United States and Puerto Rico only. Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States and Puerto Rico.

Capitalized product names are trademarks of Ortho-McNeil Neurologics^®